10.21147/j.issn.1000-9604.2023.04.06
Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence
risk、safety、high、with、adjuvant、anlotinib、carcinoma、efficacy、hepatocellular、patients
35
R322.11;TN386.3;TS974
2023-10-08(万方平台首次上网日期,不代表论文的发表时间)
共9页
399-407